Next Article in Journal / Special Issue
Examining the Clinical Effectiveness of Non-Carbapenem β-Lactams for the Treatment of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae
Previous Article in Journal
Genetic Screen Reveals the Role of Purine Metabolism in Staphylococcus aureus Persistence to Rifampicin
Previous Article in Special Issue
Remote Antimicrobial Stewardship in Community Hospitals
Article Menu

Export Article

Open AccessArticle
Antibiotics 2015, 4(4), 643-652; doi:10.3390/antibiotics4040643

Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy

1
Pharmacy Services, University of Kentucky HealthCare, 800 Rose Street, H110, Lexington, KY 40536, USA
2
College of Pharmacy, University of Kentucky, Biological Pharmaceutical Building, 789 S. Limestone Street, Lexington, KY 40536, USA
3
College of Graduate Health Sciences, University of Tennessee, 920 Madison Avenue, Suite 407, Memphis, TN 38163, USA
These authors contributed equally to this work.
This work was completed while Dr. Rybak was a trainee at University of Kentucky HealthCare.
*
Author to whom correspondence should be addressed.
Academic Editors: Jerod Nagel and Angela Huang
Received: 29 September 2015 / Revised: 24 November 2015 / Accepted: 3 December 2015 / Published: 11 December 2015
(This article belongs to the Special Issue Antimicrobial Stewardship)
View Full-Text   |   Download PDF [709 KB, uploaded 11 December 2015]   |  

Abstract

Pseudomonas aeruginosa is a common pathogen implicated in nosocomial infections with increasing resistance to a limited arsenal of antibiotics. Monte Carlo simulation provides antimicrobial stewardship teams with an additional tool to guide empiric therapy. We modeled empiric therapies with antipseudomonal β-lactam antibiotic regimens to determine which were most likely to achieve probability of target attainment (PTA) of ≥90%. Microbiological data for P. aeruginosa was reviewed for 2012. Antibiotics modeled for intermittent and prolonged infusion were aztreonam, cefepime, meropenem, and piperacillin/tazobactam. Using minimum inhibitory concentrations (MICs) from institution-specific isolates, and pharmacokinetic and pharmacodynamic parameters from previously published studies, a 10,000-subject Monte Carlo simulation was performed for each regimen to determine PTA. MICs from 272 isolates were included in this analysis. No intermittent infusion regimens achieved PTA ≥90%. Prolonged infusions of cefepime 2000 mg Q8 h, meropenem 1000 mg Q8 h, and meropenem 2000 mg Q8 h demonstrated PTA of 93%, 92%, and 100%, respectively. Prolonged infusions of piperacillin/tazobactam 4.5 g Q6 h and aztreonam 2 g Q8 h failed to achieved PTA ≥90% but demonstrated PTA of 81% and 73%, respectively. Standard doses of β-lactam antibiotics as intermittent infusion did not achieve 90% PTA against P. aeruginosa isolated at our institution; however, some prolonged infusions were able to achieve these targets. View Full-Text
Keywords: antimicrobial stewardship; pharmacodynamics; Pseudomonas aeruginosa; pharmacokinetics; modeling antimicrobial stewardship; pharmacodynamics; Pseudomonas aeruginosa; pharmacokinetics; modeling
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Tennant, S.J.; Burgess, D.R.; Rybak, J.M.; Martin, C.A.; Burgess, D.S. Utilizing Monte Carlo Simulations to Optimize Institutional Empiric Antipseudomonal Therapy. Antibiotics 2015, 4, 643-652.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibiotics EISSN 2079-6382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top